|
|
|
| Relationship between MiR-221-3p and Restenosis after Interventional Therapy for Arteriosclerosis Obliterans of Lower Extremities |
| BAI You-yi |
| Zhenping County Hospital,Shaanxi Zhenping,725600 |
|
|
|
|
Abstract 【Objective】 To investigate the effect of MiR-221-3p expression on restenosis among patients with lower extremity arteriosclerosis obliterans (LEASO). 【Methods】 The expression of mir-221-3p in serum was detected by quantitative real-time PCR in 206 patients with leaso from March 2016 to September 2018, and their restenosis was followed up. The working characteristic curve (ROC) of subjects was drawn and the predictive value of MiR-221-3p was evaluated. The risk factors of restenosis were analyzed by multivariate regression. 【Results】 In the follow-up of 6 months after interventional therapy, there were 40 restenosis cases (restenosis group) and 166 non restenosis cases (non restenosis group). The expression level of MiR-221-3p in the restenosis group was higher than that in the non restenosis group, and the proportion of age, BMI, LDL-C, diabetes, hypertension and coronary heart disease in the restenosis group was higher than that in the non restenosis group (P<0.05). The best critical point for MiR-221-3p to predict restenosis was 0.6, and the area under AUC curve was 0.62. The sensitivity and specificity of MiR-221-3p were 52.5% and 71.1%, respectively. Cox multivariate regression analysis showed that older age, obesity, hypertension, diabetes, coronary heart disease and high expression of MiR-221-3p (≥ 0.6) increased the risk of restenosis after interventional therapy (P<0.05).【Conclusion】 The expression level of MiR-221-3p is an independent risk factor for restenosis after interventional therapy in patients with leaso. The risk of restenosis is high in patients with increased expression of MiR-221-3p.
|
|
Received: 14 February 2019
|
|
|
|
|
|
[1] KLEINEGRIS M CF,TEN CATE H,TEN CATE-HOEK A J. D-dimer as a marker for cardiovascular and arterial thrombotic events in patients with peripheral arterial disease[J].Thromb Haemost,2013, 110(2):233-243.
[2] GUO B, TAN Q, GUO D, et al. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease[J].J Vascular Surg,2014, 60(4):993-1001.
[3] LI F,XU J W,WANG L,et al. MicroRNA-221-3p is up-regulated and serves as a potential biomarker in pancreatic cancer[J].Artif Cells Nanomed Biotechnol,2018,46(3):482-487.
[4] HUANG S C,WANG M,WU W B,et al. Mir-22-3p Inhibits Arterial Smooth Muscle Cell Proliferation and Migration and Neointimal Hyperplasia by Targeting HMGB1 in Arteriosclerosis Obliterans[J].Cell Physiol Biochem,2017,42(6):2492-2506.
[5] LUNARDI M,ZIVELONGHI C,BRINK F S V D,et al. Drug Eluting Balloon for the treatment of patients with Coronary Artery Disease: current perspectives[J].Cardiovasc Revasc Med,2017, 19(2):215-220.
[6] ZHANG X,SHAO S,GENG H,et al. Expression profiles of six circulating MicroRNAs critical to atherosclerosis in patients with subclinical hypothyroidism: a clinical study[J].J Clin Endocrinol Metab,2014, 99(5):E766-E774.
[7] LIU X. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia[J].Circ Res,2009, 104(4):476-487.
[8] OLIN JW, SEALOVE BA. Peripheral artery disease: current insight into the disease and its diagnosis and management[J].Mayo Clin Proc,2010, 85(7):678-692.
[9] FAGLIA E, CLERICI G,CLERISSI J,et al. Long-Term Prognosis of Diabetic Patients With Critical Limb Ischemia[J].Diabetes Care,2009, 32(5):822-827.
[10] HE M, GONG Y T,SHI J,et al. Plasma MicroRNAs as potential noninvasive biomarkers for in-stent restenosis[J].PLoS One,2014, 9(11):e112043. |
|
|
|
2021, Vol. 38 
